Treating Metastatic breast cancer with systemic chemotherapies: Current trends and future perspectives

Clinical Journal of Oncology Nursing

Volumn 16, Issue 2, 2012, Pages

  Smith, Nancy Zeller ^a  

^a Landstuhl Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; DRUG RESISTANCE; FEMALE; HUMAN; METASTASIS; NURSING EDUCATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EDUCATION, NURSING, CONTINUING; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 84859201596     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/12.CJON.E33-E43     Document Type: Article

References (105)

1. Anders, C.K., & Carey, L.A. (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer, 9(Suppl. 2), S73-S81. doi:10.3816/CBC.2009.s.008
2. Annunziata, C.M., & O'Shaughnessy, J. (2010). Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clinical Cancer Research, 16, 4517-4526. doi:10.1158/1078-0432.CCR-10-0526
3. Atchley, D.P., Albarracin, C.T., Lopez, A., Valero, V., Amos, C.I., Gonzalez-Angulo A.M.... Arun, B.K. (2008). Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology, 26, 4282-4288. doi:10.1200/JCO.2008.16.6231
4. Baselga, J., Cortés, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H.,... Swain, S.M. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine, 366, 109-119.
5. Baselga, J., Zambetti, M., Llombart-Cussac, A., Manikhas, G., Kubista E, Steger, G.G.,... Galbraith, S. (2009). Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 27, 526-534. doi:10.1200/JCO.2007.14.2646
6. Blackwell, K.L., Burstein, H.J., Storniolo, A.M., Rugo, H., Sledge, G., Koehler, M.,... O'Shaughnessy, J. (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology, 28, 1124-1130. doi:10.1200/JCO.2008.21.4437
7. Blum, J.L., Direras, V., Lo Russo, P.M., Horton, J., Rutman, O., Buzdar A., & Osterwalder, B. (2001). Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92, 1759-1768. doi:10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
8. Blum, J.L., Jones, S.E., Buzdar, A.U., LoRusso, P.M., Kuter, I., Vogel C,... Brown, C.S. (1999). Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. Journal of Clinical Oncology, 17, 485-493.
9. Bonneterre, J., Thürlimann, B., Robertson, J.F., Krzakowski, M., Mauriac, L., Koralewski, P.,... von Euler, M. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimdex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology, 18, 3748-3757.
10. ® (paclitaxel) injection [Prescribing information]. Princeton, NJ: Author.
11. ® kit (ixabepilone) [Prescribing information]. Princeton, NJ: Author.
12. Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu C.G,... Geyer, C.E. (2008). A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Research and Treatment, 112, 533-543. doi:10.1007/s10549-007-9885-0
13. Cardoso, F., Bedard, P.L., Winer, E.P., Pagani, O., Senkus-Konefka, E., Fallowfield, L.J.,... ESO-MBC Task Force. (2009). International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. Journal of the National Cancer Institute, 101, 1174-1181. doi:10.1093/jnci/djp235
14. Carey, L.A., Rugo, H.S., Marcom, P.K., Irvin, W., Ferraro, M., Burrows E.,... Perou, E.P. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer [Abstract 1009]. Journal of Clinical Oncology, 26(Suppl.), 43s.
15. Carrick, S., Parker, S., Thornton, C.E., Ghersi, D., Simes, J., & Wilcken N (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systemic Reviews, 2, CD003372.
16. Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M.,... Piccart, M. (2008). Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. Journal of Clinical Oncology, 26, 1664-1670. doi:10.1200/JCO.2007.13.5822
17. Comen, E.A., & Robson, M. (2010). Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology, 24, 55-62.
18. Conte, P., Guarneri, V., & Bengala, C. (2007). Evolving nonendocrine therapeutic options for metastatic breast cancer: How adjuvant chemotherapy influences treatment. Clinical Breast Cancer, 7, 841-849.
19. Cortés, J., O'Shaughnessy, J., Loesch, D., Blum, J.L., Vahdat, L.T., Petrakova, K.,... EMBRACE Investigators. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet, 377, 914-923. doi:10.1016/S0140-6736(11)60070-6
20. Cortés, J., Vahdat, L., Blum, J.L., Twelves, C., Campone, M., Roché, H.,... Allison, M.A. (2010). Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 28, 3922-3928. doi:10.1200/JCO.2009.25.8467
21. Denduluri, N., Low, J.A., Lee, J.J., Berman, A.W., Walshe, J.M., Vatas U,... Swain, S.M. (2007). Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. Journal of Clinical Oncology, 25, 3421-3427. doi:10.1200/JCO.2006.10.0784
22. Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I.N., Khasanov, R.,... Martin, M. (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology, 28, 4594-4600. doi:10.1200/JCO.2010.28.8415
23. ® (eribulin mesylate) [Prescribing information]. Woodcliff Lake, NJ: Author.
24. Ferrazzi, E., & Stievano, L. (2006). Gemcitabine: Monochemotherapy of breast cancer. Annals of Oncology, 17(Suppl. 5), v169-v172. doi:10.1093/annonc/mdj975
25. Fojo, T., & Menefee, M. (2007). Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Annals of Oncology, 18(Suppl. 5), v3-v8.
26. Foulkes, W.D., Smith, I.E., & Reis-Filho, J.S. (2010). Triple-negative breast cancer. New England Journal of Medicine, 363, 1938-1948. doi:10.1056/NEJMra1001389
27. Frasci, G., Comella, P., Rinaldo, M., Iodice, G., Di Bonito, M., D'Aiuto, M.,... D'Aiuto, G. (2009). Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Annals of Oncology, 20, 1185-1192. doi:10.1093/annonc/mdn748
28. Fumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T.,... Namer, M. (2004). Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. European Journal of Cancer, 40, 536-542. doi:10.1016/j.ejca.2003.11.007
29. ® (capecitabine) tablets [Prescribing information]. Nutley, NJ: Author.
30. Geyer, C.E., Foster, J., Lindquist, D., Chan, S., Romieu, C.G., Pienkowski T,... Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New England Journal of Medicine, 355, 2733-2743. doi:10.1056/NEJMoa064320
31. Gressett, S.M., Stanford, B.L., & Hardwicke, F. (2006). Management of hand-foot syndrome induced by capecitabine. Journal of Oncology Pharmacy Practice, 12, 131-141.
32. Guler, G., Himmetoglu, C., Jimenez, R.E., Geyer, S.M., Wang, W.P., Costinean, S.,... Huebner, K. (2011). Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Research and Treatment, 129, 421-432. doi:10.1007/s10549-010-1248-6
33. Hensley, M.L., Hagerty, K.L., Kewalramani, T., Green, D.M., Meropol N.J., Wasserman, T.H,... Schuchter, L.M. (2009). American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology, 27, 127-145. doi:10.1200/JCO.2008.17.2627
34. Hortobagyi, G.N., Gomez, H.L., Li, R.K., Chung, H.C., Fein, L.E., Chan, V.F.,... Roché, H.H. (2010). Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment, 122, 409-418. doi:10.1007/s10549-010-0901-4
35. Hudis, C.A., & Gianni, L. (2011). Triple-negative breast cancer: An unmet medical need. Oncologist, 16(Suppl. 1), 1-11.
36. Ingle, J.N., Suman, V.J., Rowland, K.M., Mirchandani, D., Bernath, A.M., Camoriano, J.K.,... North Central Cancer Treatment Group Trial N0032. (2006). Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. Journal of Clinical Oncology, 24, 1052-1056. doi:10.1200/JCO.2005.04.1053
37. Jassem, J., Carroll, C., Ward, S.E., Simpson, E., & Hind, D. (2009). The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review. European Journal of Cancer, 45, 2749-2758. doi:10.1016/j.ejca.2009.05.035
38. Junttila, T.T., Li, G., Parsons, K., Phillips, G.L., & Sliwkowski, M.X. (2011). Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment, 128, 347-356. doi:10.1007/s10549-010-1090-x
39. Kamath, K., Wilson, L., Cabral, F., & Jordan, M.A. (2005). BIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. Journal of Biological Chemistry, 280, 12902-12907. doi:10.1074/jbc.M414477200
40. Klijn, J.G., Blamey, R.W., Boccardo, F., Tominaga, T., Duchateau, L., Sylvester, R., & Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. (2001). Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. Journal of Clinical Oncology, 19, 343-353.
41. Koshy, N., Quispe, D., Shi, R., Mansour, R., & Burton, G.V. (2010). Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast, 19, 246-248. doi:10.1016/j.breast.2010.02.003
42. Laessig, D., Stemmler, H.J., Vehling-Kaiser, U., Fasching, P.A., Melchert, F., Kolbl, H.,... Heinemann, V. (2007). Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology, 73, 407-414. doi:10.1159/000136796
43. Lassere, Y., & Hoff, P. (2004). Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). European Journal of Oncology Nursing, 8(Suppl. 1), S31-S40. doi:10.1016/j.ejon.2004.06.007
44. Lee, F.Y., Borzilleri, R., Fairchild, C.R., Kim, S.H., Long, B.H., Reventos-Suarez, C.,... Kramer, R.A. (2001). BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clinical Cancer Research, 7, 1429-1437.
45. Lee, F.Y., Smykla, R., Johnston, K., Menard, K., McGlinchey, K., Peterson, R.W.,... Kramer, R. (2009). Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemotherapy and Pharmacology, 63, 201-212. doi:10.1007/s00280-008-0727-5
46. Lee, J.J., & Swain, S.M. (2006). Peripheral neuropathy induced by microtubule-stabilizing agents. Journal of Clinical Oncology, 24, 1633-1642. doi:10.1200/JCO.2005.04.0543
47. Lerma, E., Peiro, G., Ramón, T., Fernandez, S., Martinez, D., Pons, C.,... Barnadas, A. (2007). Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Modern Pathology, 20, 1200-1207. doi:10.1038/modpathol.3800961
48. Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E.,... Sliwkowski, M.X. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Research, 68, 9280-9290. doi:10.1158/0008-5472.CAN-08-1776
49. Liu, X., Shi, Y., Maag, D.X., Palma, J.P., Patterson M.J., Ellis, P.A.,... Shoemaker, A.R. (2012). Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clinical Cancer Research, 18, 510-523.
50. Low, J.A., Wedam, S.B., Lee, J.J., Berman, A.W., Brufsky, A., Yang, S.X.,... Swain, S.M. (2005). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 23, 2726-2734. doi:10.1200/JCO.2005.10.024
51. Mannocci, A., De Feo, E., de Waure, C., Specchia, M.L., Gualano, M.R., Barone, C.,... La Torre, G. (2010). Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: A systematic review of published studies. Tumori, 96, 385-391.
52. Martin, M., Ruiz, A., Muñoz, M., Balil, A., García-Mata, J., Calvo, L.,... Spanish Breast Cancer Research Group (GEICAM) trial. (2007). Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncology, 8, 219-225. doi:10.1016/S1470-2045(07)70041-4
53. Milano, G., Etienne-Grimaldi, M.C., Mari, M., Lassalle, S., Formento, J.L., Francoual, M.,... Hofman, P. (2008). Candidate mechanisms for capecitabine-related hand-foot syndrome. British Journal of Clinical Pharmacology, 66, 88-95. doi:10.1111/j.1365-2125.2008.03159.x
54. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A.,... Davidson, N.E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 357, 2666-2676. doi:10.1056/NEJMoa072113
55. Modi, S., Currie, V.E., Seidman, A.D., Bach, A.M., Panageas, K.S., Theodoulou, M.,... Hudis, C.A. (2005). A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical Breast Cancer, 6, 55-60. doi:10.3816/CBC.2005.n.009
56. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A.,... Bhatnagar, A. (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology, 21, 2101-2109. doi:10.1200/JCO.2003.04.194
57. Nagourney, R.A., Flam, M., Link, J., Hager, S., Blitzer, J., Lyons, W.,... Evans, S. (2008). Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clinical Breast Cancer, 8, 432-435. doi:10.3816/CBC.2008.n.052
58. Nahta, R., Hung, M.C., & Esteva, F.J. (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Research, 64, 2343-2346. doi:10.1158/0008-5472.CAN-03-3856
59. National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology: Breast cancer [v.2.2011]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
60. Niculescu-Duvaz, I. (2010). Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Current Opinion in Molecular Therapeutics, 12, 350-360.
61. O'Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.P., Cervantes, G.,... Leonard, R. (2002). Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. Journal of Clinical Oncology, 20, 2812-2823. doi:10.1200/JCO.2002.09.002
62. O'Shaughnessy, J., Osborne, C., Pippen, J.M., Yoffe, M., Patt, D., Rocha, C.,... Bradley, C. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New England Journal of Medicine, 364, 205-214.
63. O'Shaughnessy, J., Schwartzberg, L.S, Danso, M.A., Rugo, H.S., Miller, K., Yardley, D.A.,... Winer, E.P. (2011). A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [Abstract 1007]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78038
64. Paradiso, A., Mangia, A., Chiriatti, A., Tommasi, S., Zito, A., Latorre, A.,... Lorusso, V. (2005). Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Annals of Oncology, 16(Suppl. 4), 414-419.
65. Paridaens, R.J., Dirix, L.Y., Beex, L.V., Nooij, M., Cameron, D.A., Cufer, T.,... Therasse, P. (2008). Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology, 26, 4883-4890. doi:10.1200/JCO.2007.14.4659
66. Patel, A.G., De Lorenzo S.B., Flatten K.S., Poirier G.G., & Kaufmann, S.H. (2012). Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clinical Cancer Research. Advance online publication. doi:10.1158/1078-0432.CCR-11-2890
67. Perey, L., Paridaens, R., Hawle, H., Zaman, K., Nolé, F., Wildiers, H.,... Thürlimann, B. (2007). Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Annals of Oncology, 18, 64-69. doi:10.1093/annonc/mdl341
68. Perez, E.A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman L.,... Hortobagyi, G.N. (2007). Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 25, 3407-3414. doi:10.1200/JCO.2006.09.3849
69. Perez, E.A., Patel, T., & Moreno-Aspitia, A. (2010). Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Research and Treatment, 121, 261-271. doi:10.1007/s10549-010-0824-0
70. Pfeffer, B., Tziros, C., & Katz, R.J. (2009). Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention. British Journal of Cardiology, 16, 85-89.
71. Piccart-Gebhart, M.J., Burzykowski, T., Buyse, M., Sledge, G., Carmicael J., Lück, H.J.,... Therasse, P. (2008). Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. Journal of Clinical Oncology, 26, 1980-1986. doi:10.1200/JCO.2007.10.8399
72. Pintens, S., Neven, P., Drijkoningen, M., Van Belle, V., Moerman, P., Christiaens, M.R.,... Bempt, I.V. (2009). Triple negative breast cancer: A study from the point of view of basal CK 5/6 and HER-1. Journal of Clinical Pathology, 62, 624-628. doi:10.1136/jcp.2008.061358
73. Reichardt, P., Von Minckwitz, G., Thuss-Patience, P.C., Jonat, W., Kölbl, H., Jänicke, F.,... Lück, H.J. (2003). Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Annals of Oncology, 14, 1227-1233. doi:10.1093/annonc/mdg346
74. Rivera, E., Lee, J., & Davies, A. (2008). Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist, 13, 1207-1223. doi:10.1634/theoncologist.2008-0143
75. Roché, H., Yelle, L., Cognetti, F., Mauriac, L., Bunnell, C., Sparano, J.,... Curé, H. (2007). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of Clinical Oncology, 25, 3415-3420. doi:10.1200/JCO.2006.09.7535
76. ® (docetaxel) injections concentrate [Prescribing information]. Bridgewater, NJ: Author.
77. Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Research, 69, 9330-9336. doi:10.1158/0008-5472.CAN-08-4597
78. Shen, H., Lee, F.Y., & Gan, J. (2011). Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). Journal of Pharmacology and Experimental Therapeutics, 337, 423-432. doi:10.1124/jpet.110.175604
79. Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29. doi:10.3322/caac.20138
80. Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q.,... Garber, J.E. (2010). Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. Journal of Clinical Oncology, 28, 1145-1153. doi:10.1200/JCO.2009.22.4725
81. Sparano, J.A., Vrdoljak, E., Rixe, O., Xu, B., Manikhas, A., Medina, C.,... Conte, P. (2010). Randomized phase III trial of ixabepilone plus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 28, 3256-3263. doi:10.1200/JCO.2009.24.4244
82. Spielmann, M., Llombart-Cussac, A., Kalla, S., Espié, M., Namer, M., Ferrero, J.M.,... Pouillart, P. (2001). Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology, 60, 303-307. doi:10.1159/000058524
83. Surveillance Epidemiology and End Results. (2012). SEER stat fact sheets: Breast. Retrieved from http://seer.cancer.gov/statfacts/html/breast.html
84. Tan, S.H., & Wolff, A.C. (2007). Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clinical Breast Cancer, 7, 455-464. doi:10.3816/CBC.2007.n.002
85. Taur, J.S., Desjardins, C.S., Schuck, E.L., & Wong, Y.N. (2010). Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica, 41, 320-326. doi:10.3109/00498254.2010.542256
86. Telli, M.L., & Ford, J.M. (2010). Novel treatment approaches for triple-negative breast cancer. Clinical Breast Cancer, 10(Suppl. 1), E16-E22. doi:10.3816/CBC.2010.s.003
87. Thike, A.A., Cheok, P.Y., Jara-Lazaro, A.R., Tan, B., Tan, P., & Tan, P.H. (2010). Triple-negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Modern Pathology, 23, 123-133. doi:10.1038/modpathol.2009.145
88. Thomas, E., Gomez, H.L., Li, R.K., Chung, H.C., Fein, L.E., Chan, V.F.,... Roché, H.H. (2007). Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 25, 5210-5217. doi:10.1200/JCO.2007.12.6557
89. Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A.,... Martin, M. (2007). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 25, 3399-3406. doi:10.1200/JCO.2006.08.9102
90. Tommasi, S., Mangia, A., Lacalamita, R., Bellizzi, A., Fedele, V., Chiriatti, A.,... Paradiso, A. (2007). Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins. International Journal of Cancer, 120, 2078-2085. doi:10.1002/ijc.22557
91. Torrisi, R., Balduzzi, A., Ghisini, R., Rocca, A., Bottiglieri, L., Giovanardi, F.,... Colleoni, M. (2008). Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemotherapy and Pharmacology, 62, 667-672. doi:10.1007/s00280-007-0652-z
92. Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N.,... Carmichael, J. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet, 376, 235-244. doi:10.1016/S0140-6736(10)60892-6
93. Twelves, C., Cortes, J., Vahdat, L.T., Wanders, J., Akerele, C., & Kaufman, P.A. (2010). Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer, 10, 160-163.
94. U.S. Food and Drug Administration. (2011). FDA commissioner announces Avastin decision: Drug not shown to be safe and effective in breast cancer patients. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm
95. Vahdat, L. (2008). Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist, 13, 214-221. doi:10.1634/theoncologist.2007-0167
96. Vahdat, L.T., Pruitt, B., Fabian, C.J., Rivera, R.R., Smith, D.A., Tan-Chiu, E.,... Blum, J.L. (2009). Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 27, 2954-2961. doi:10.1200/JCO.2008.17.7618
97. Valachis, A., Polyzos, N.P., Patsopoulos, N.A., Georgoulias, V., Mavroudis, D., & Mauri, D. (2010). Bevacizumab in metastatic breast cancer: A meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment, 122, 1-7.
98. Valero, V., Bosserman, L., Yardley, D., Roche, H.H., Thomas, E., Vahdat L.T.,... Sparano, J. (2010). Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048) [Abstract 1051]. Journal of Clinical Oncology, 28(15, Suppl.) 126s.
99. von Minckwitz, G., Du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F.T.,... Loibl, S. (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international group 03-05 study. Journal of Clinical Oncology, 27, 1999-2006.
100. von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke C., Cufer, T.,... Loibl, S. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer, 47, 2273-2281.
101. Walker, J.R., Singal, P.K., & Jassal, D.S. (2009). The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. Experimental and Clinical Cardiology, 14, e62-e67.
102. Yardley, D.A. (2009). Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist, 14, 448-455.
103. Yardley, D.A., Burris, H.A., 3rd, Simons, L., Spigel, D.R., Greco, F.A., Barton, J.H.,... Hainsworth, J.D. (2008). A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clinical Breast Cancer, 8, 425-431. doi:10.3816/CBC.2008.n.051
104. Zelek, L., Barthier, S., Riofrio, M., Fizazi, K., Rixe, O., Delord, J.P.,... Spielmann, M. (2001). Weekly vinorelbine is an effective palliative regimen after failure of anthracyclines and taxanes in metastatic breast carcinoma. Cancer, 92, 2267-2272.
105. Zhang, J., & Powell, S.N. (2005). The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Molecular Cancer Research, 3, 531-539. doi:10.1158/1541-7786.MCR-05-0192